Of the initial 8 evaluable patients in the pembrolizumab cohort, there was 1PR with 48% tumor reduction at first evaluation (NSCLC, PD-L1 <10%, CPI-refractory), 2SD (NSCLC, PD-L1 0%, > 24 weeks; appendiceal cancer, MSS). The gene discussed is CD274; the disease is neoplasm.